Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAngthong C.
dc.contributor.authorKhadsongkram A.
dc.contributor.authorAngthong W.
dc.description.abstractThe present study aimed to determine the outcomes and quality of life after platelet-rich plasma therapy in patients with chronic recalcitrant diseases of the hindfoot and ankle and to identify the crucial clinical variables. The records of 12 adult patients with diseases of the hindfoot and ankle were included in the present study. These patients had been treated with platelet-rich plasma from September 2010 to April 2011 after 3 to 6months or more of conservative treatment had been unsuccessful. They had attended the follow-up visits, were consecutively enrolled, and retrospectively studied. A total of 3 mL of autologous platelet-rich plasma was injected under fluoroscopic or ultrasound guidance into the affected areas. All patients had been evaluated using visual analog scale foot and ankle scoring before treatment and at set intervals after treatment. According to their scores at the final follow-up visit (mean 16 months), the patients were allocated to the satisfactory (score ≥ 80; n = 8) and unsatisfactory (score < 80; n = 4) groups. The health-related quality of life was assessed using the Medical Outcomes Study short-form, 36-item survey at the final follow-up visit, because the study was retrospective, and the information was not available before treatment. The mean visual analog score at the final follow-up visit (79.71 ± 17.81) was significantly greater than the mean pretreatment score (57.89 ± 20.77; p = .002). Four patients (33%) had unsatisfactory results. The mean short-form, 36-item score for the satisfactory group (85.23 ± 11.30) was significantly greater than that (57.33 ± 12.91) of the unsatisfactory group (p=003). No definitive factors influencing the outcome of this treatment were found. The substantial number of patients with an unsatisfactory outcome indicates that platelet-rich plasma injection might be an option but might not be a mainstay of nonoperative treatment of problematic conditions of the hindfoot and ankle. The actual benefit of this treatment, including the factors influencing its outcome, are still inconclusive. © 2013 American College of Foot and Ankle Surgeons.
dc.subjectachilles tendinitis
dc.subjectankle osteoarthritis
dc.subjectclinical article
dc.subjectclinical effectiveness
dc.subjectconservative treatment
dc.subjectcontrolled study
dc.subjectfoot disease
dc.subjectnuclear magnetic resonance imaging
dc.subjectquality of life
dc.subjectrecalcitrant disease of the hindfoot and ankle
dc.subjectretrocalcaneal bursitis
dc.subjectretrospective study
dc.subjectscoring system
dc.subjectShort Form 36
dc.subjectthrombocyte rich plasma
dc.subjecttreatment duration
dc.subjecttreatment response
dc.subjectvisual analog scale
dc.subjectAnkle Joint
dc.subjectFollow-Up Studies
dc.subjectJoint Diseases
dc.subjectMiddle Aged
dc.subjectPatient Satisfaction
dc.subjectPlatelet-Rich Plasma
dc.subjectQuality of Life
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.subjectYoung Adult
dc.titleOutcomes and quality of life after platelet-rich plasma therapy in patients with recalcitrant hindfoot and ankle diseases: A preliminary report of 12 patients
dc.identifier.bibliograpycitationJournal of Foot and Ankle Surgery. Vol 52, No.4 (2013), p.475-480
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.